HIGHLIGHTS
SUMMARY
Treatment is key to patient management, as H. pylori is responsible for histopathological cascades to cancer, which have been reported in large-scale epidemiological studies and reinforced by in_vitro and in_vivo studies. Most infected patients receive empirical treatment with a proton pump inhibitor combined with dual antibiotics (tetracycline- metronidazole) or even triple antibiotics (amoxicillin-clarithromycin-metronidazole) combined with bismuth salts or dual antibiotics (amoxicillin-clarithromycin) without bismuth salts. In view of the very large number of mutations that have been associated in_vitro/in_vivo/in silico with antibiotic resistance, it is time to set up . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.